Abstract
To investigate whether the use of a steroid-sparing antiemetic protocol (substituting dexamethasone with olanzapine) affects the incidence of neutropenia and associated hospital admissions in patients receiving bleomycin, etoposide and cisplatin (BEP) chemotherapy. Records from 108 patients who received BEP at St Bartholomew's Hospital, London were divided into two groups according to antiemetic regimen. Group 1 (treated 2008-2013) were treated with a steroid-containing antiemetic protocol and group 2 (treated 2014-2017) were treated according to a steroid-sparing protocol, i.e. using olanzapine. Outcomes included incidence of neutropenia at nadir blood count, severity of neutropenia, hospital admissions attributable to febrile neutropenia (FN) and baseline risk factors associated with FN. Statistical analyses were performed using two-sided chi-squared tests. The baseline characteristics of the two groups were balanced with regard to age, gender, histology, and proportion of patients with International Germ Cell Cancer Collaborative Group poor-risk disease. The incidence of neutropenia of any grade (group 1, 96.2%; group 2, 98.1%) was similar, although group 2 had more patients with severe neutropenia than group 2 (77.7% vs 88....Continue Reading
References
Apr 1, 1978·Annals of Internal Medicine·C G Craddock
Mar 1, 1976·Annals of Internal Medicine·A S FauciJ E Balow
Dec 1, 1974·The Journal of Clinical Investigation·J J RinehartA F LoBuglio
May 1, 1984·Cellular Immunology·T L GerrardA S Fauci
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S D FossåL Collette
Nov 24, 1998·Circulation·M NakagawaS F van Eeden
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R de WitL Collette
Apr 1, 2006·Cancer·Nicole M KudererGary H Lyman
Jun 6, 2008·The New England Journal of Medicine·Paul J Hesketh
Sep 25, 2009·Journal of Experimental & Clinical Cancer Research : CR·Lijun TanDaxin Zhang
Oct 26, 2011·The Journal of Supportive Oncology·Rudolph M NavariAndrew C Kerr
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J OldenburgUNKNOWN ESMO Guidelines Working Group
Jan 1, 2013·Molecular and Clinical Oncology·Shinya AokiYoshinori Itoh
Oct 2, 2015·BioMed Research International·Praveen RanganathCostantine Albany
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F RoilaUNKNOWN participants of the MASCC/ESMO Consensus Conference Copenhagen 2015
Oct 1, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Rae Young KangYu Jeung Lee
Jul 9, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Michael J BergerMiranda Hughes
Jan 20, 2018·Cancer Medicine·Angelika TerbuchMichael Stotz
Oct 17, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Leila FamilyChun Chao
Dec 16, 2019·The Lancet Oncology·Hironobu HashimotoYuichiro Ohe